What is a stock summary page? Click here for an overview.
Business Description
Xeris Biopharma Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US98422E1038
Description
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | -0.09 | |||||
| Debt-to-Equity | -9.17 | |||||
| Debt-to-EBITDA | -19.4 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.22 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 30.1 | |||||
| 3-Year EBITDA Growth Rate | 59.6 | |||||
| 3-Year EPS without NRI Growth Rate | 36.3 | |||||
| 3-Year FCF Growth Rate | 40.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 22.34 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 16.04 | |||||
| 9-Day RSI | 26.21 | |||||
| 14-Day RSI | 34.97 | |||||
| 3-1 Month Momentum % | 28.72 | |||||
| 6-1 Month Momentum % | 54.23 | |||||
| 12-1 Month Momentum % | 120.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.67 | |||||
| Quick Ratio | 1.19 | |||||
| Cash Ratio | 0.71 | |||||
| Days Inventory | 428.08 | |||||
| Days Sales Outstanding | 72.11 | |||||
| Days Payable | 67.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | -7.24 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.86 | |||||
| Operating Margin % | -16.57 | |||||
| Net Margin % | -27 | |||||
| FCF Margin % | -18.64 | |||||
| ROA % | -16.77 | |||||
| ROIC % | -15.01 | |||||
| 3-Year ROIIC % | 286.29 | |||||
| ROC (Joel Greenblatt) % | -59.53 | |||||
| ROCE % | -11.09 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.01 | |||||
| EV-to-EBIT | -31.56 | |||||
| EV-to-Forward-EBIT | 140.74 | |||||
| EV-to-EBITDA | -60.04 | |||||
| EV-to-Revenue | 4.14 | |||||
| EV-to-Forward-Revenue | 3.16 | |||||
| EV-to-FCF | -22.2 | |||||
| Price-to-GF-Value | 1.16 | |||||
| Earnings Yield (Greenblatt) % | -3.17 | |||||
| FCF Yield % | -5.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xeris Biopharma Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 203.07 | ||
| EPS (TTM) ($) | -0.38 | ||
| Beta | 0.03 | ||
| 3-Year Sharpe Ratio | 0.61 | ||
| 3-Year Sortino Ratio | 1.03 | ||
| Volatility % | 56.57 | ||
| 14-Day RSI | 34.97 | ||
| 14-Day ATR ($) | 0.293741 | ||
| 20-Day SMA ($) | 5.04555 | ||
| 12-1 Month Momentum % | 120.33 | ||
| 52-Week Range ($) | 1.7 - 5.9992 | ||
| Shares Outstanding (Mil) | 153.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xeris Biopharma Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xeris Biopharma Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xeris Biopharma Holdings Inc Frequently Asked Questions
What is Xeris Biopharma Holdings Inc(LTS:0A8E)'s stock price today?
The current price of LTS:0A8E is $3.95. The 52 week high of LTS:0A8E is $6.00 and 52 week low is $1.70.
When is next earnings date of Xeris Biopharma Holdings Inc(LTS:0A8E)?
The next earnings date of Xeris Biopharma Holdings Inc(LTS:0A8E) is 2025-05-09 Est..
Does Xeris Biopharma Holdings Inc(LTS:0A8E) pay dividends? If so, how much?
Xeris Biopharma Holdings Inc(LTS:0A8E) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers